By vgreene, 8 July, 2020 Study considerations retrospective small sample size historical bias imbalanced baseline characteristics
By vgreene, 8 July, 2020 Composite primary outcome of mech vent or death: anakinra 25% vs SOC 73% (hazard ratio 0.22, 95% CI 0.1-0.49); elevated LFTs w/ anakinra 13% vs SOC 9%; similar results observed for death alone or need for mech vent alone
By vgreene, 8 July, 2020 Retrospective cohort study; 96 hospitalized non-ICU pts w/ severe COVID-19 managed w/ SOC, incl HCQ, AZ, other abx, CS, DVT prophylaxis; prospective cohort of 52 pts received anakinra (100 mg SC bid x72h, then 100 mg SC daily x7 days) + SOC; 44 pts as his
By vgreene, 8 July, 2020 Treatment With Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized With COVID-19
By vgreene, 8 July, 2020 Study considerations: retrospective study w/ propensity score adjusted analysis; potential for selection bias based on treatment protocol and QT-interval algorithm; high rate of CS use in HCQ-treated pts; sx duration prior to admission not available; miss
By vgreene, 8 July, 2020 Crude in-hospital mortality: overall 18.1%, HCQ 13.5%, HCQ + AZ 20.1%, AZ 22.4%, neither drug 26.4%; multivariate analysis showed significant risk reduction w/ HCQ (66%) or HCQ + AZ (71%) compared w/ neither drug; additional propensity score matched analy
By vgreene, 8 July, 2020 Retrospective, observational, multicenter study; 2,541 pts (median age 64y) w/ confirmed SARS-CoV-2 received HCQ, HCQ + AZ, AZ, or neither drug; HCQ dose: 400 mg PO bid x2 doses, then 200 mg PO bid on days 2-5; AZ dose: 500 mg PO x1, then 250 mg PO qd x4